

BioLineRx Ltd.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
(UNAUDITED)

	<u>December 31,</u> <u>2014</u>	<u>June 30,</u> <u>2015</u>
	<u>in USD thousands</u>	
Assets		
CURRENT ASSETS		
Cash and cash equivalents	5,790	9,404
Short-term bank deposits	28,890	45,385
Prepaid expenses	221	250
Other receivables	257	653
Total current assets	<u>35,158</u>	<u>55,692</u>
NON-CURRENT ASSETS		
Restricted deposits	166	-
Long-term prepaid expenses	49	57
Property and equipment, net	721	2,489
Intangible assets, net	117	117
Total non-current assets	<u>1,053</u>	<u>2,663</u>
Total assets	<u><u>36,211</u></u>	<u><u>58,355</u></u>
Liabilities and equity		
CURRENT LIABILITIES		
Accounts payable and accruals:		
Trade	1,654	2,959
Other	1,252	1,193
Total current liabilities	<u>2,906</u>	<u>4,152</u>
NON-CURRENT LIABILITIES		
Warrants	1,500	2,387
Total non-current liabilities	<u>1,500</u>	<u>2,387</u>
COMMITMENTS AND CONTINGENT LIABILITIES		
Total liabilities	<u>4,406</u>	<u>6,539</u>
EQUITY		
Ordinary shares	1,055	1,448
Share premium	167,331	195,583
Other reserves	(1,416)	(1,416)
Capital reserve	9,800	10,287
Accumulated deficit	(144,965)	(154,086)
Total equity	<u>31,805</u>	<u>51,816</u>
Total liabilities and equity	<u><u>36,211</u></u>	<u><u>58,355</u></u>

BioLineRx Ltd.
CONDENSED CONSOLIDATED INTERIM STATEMENT OF COMPREHENSIVE LOSS
(UNAUDITED)

	<u>Three months ended June 30,</u>		<u>Six months ended June 30,</u>	
	<u>2014</u>	<u>2015</u>	<u>2014</u>	<u>2015</u>
	<u>in USD thousands</u>		<u>in USD thousands</u>	
RESEARCH AND DEVELOPMENT EXPENSES, NET	(2,792)	(2,891)	(5,511)	(6,102)
SALES AND MARKETING EXPENSES	(285)	(299)	(652)	(559)
GENERAL AND ADMINISTRATIVE EXPENSES	(834)	(976)	(1,824)	(1,832)
OPERATING LOSS	(3,911)	(4,166)	(7,987)	(8,493)
NON-OPERATING INCOME (EXPENSES), NET	279	(847)	1,966	(887)
FINANCIAL INCOME	-	205	306	278
FINANCIAL EXPENSES	(435)	(2)	(467)	(19)
NET LOSS	(4,067)	(4,810)	(6,182)	(9,121)
OTHER COMPREHENSIVE LOSS:				
CURRENCY TRANSLATION DIFFERENCES	424	-	288	-
COMPREHENSIVE LOSS	(3,643)	(4,810)	(5,894)	(9,121)
	<u>in USD</u>		<u>in USD</u>	
LOSS PER ORDINARY SHARE - BASIC AND DILUTED	(0.12)	(0.09)	(0.20)	(0.19)
WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE	34,005,072	53,562,019	30,503,968	48,095,879

BioLineRx Ltd.
CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS
(UNAUDITED)

	Six months ended June 30,	
	2014	2015
	in USD thousands	
CASH FLOWS - OPERATING ACTIVITIES		
Comprehensive loss for the period	(6,182)	(9,121)
Adjustments required to reflect net cash used in operating activities (see appendix below)	(1,551)	1,976
Net cash used in operating activities	(7,733)	(7,145)
CASH FLOWS - INVESTING ACTIVITIES		
Investments in short-term deposits	(30,825)	(39,184)
Maturities of short-term deposits	15,446	22,738
Maturities of restricted deposits	-	166
Purchase of property and equipment	(88)	(1,586)
Purchase of intangible assets	(3)	(7)
Net cash used in investing activities	(15,470)	(17,873)
CASH FLOWS - FINANCING ACTIVITIES		
Issuances of share capital, net	22,612	28,645
Net cash provided by financing activities	22,612	28,645
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(591)	3,627
CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD	8,899	5,790
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS	116	(13)
CASH AND CASH EQUIVALENTS - END OF PERIOD	8,424	9,404

BioLineRx Ltd.

APPENDIX TO CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS
(UNAUDITED)

	Six months ended June 30,	
	2014	2015
	in USD thousands	
<hr/>		
Adjustments required to reflect net cash used in operating activities:		
Income and expenses not involving cash flows:		
Depreciation and amortization	139	195
Long-term prepaid expenses	2	(8)
Interest on restricted deposits	1	-
Interest and exchange rate differences on short-term deposits	238	(49)
Share-based compensation	498	487
Exchange differences on cash and cash equivalents	(63)	13
Loss (gain) on adjustment of warrants to fair value	(2,314)	887
Commitment fee paid by issuance of share capital	303	-
	<hr/>	<hr/>
	(1,196)	1,525
Changes in operating asset and liability items:		
Increase in trade accounts receivable and other receivables	(71)	(425)
Increase (decrease) in accounts payable and accruals	(284)	876
	<hr/>	<hr/>
	(355)	451
	<hr/>	<hr/>
	(1,551)	1,976
Supplementary information on investing activities not involving cash flows:		
Property and equipment acquired on supplier trade credit	-	512
	<hr/>	<hr/>
	-	512
Supplementary information on interest received in cash	<hr/>	<hr/>
	28	30
	<hr/>	<hr/>